Los Esperamos!! https://t.co/LsvzMcqJBb

Does this article mean the definitive death of aspirin in CCS?

Subanalisis of the BEST trial. IVUS guided PCI match CABG at long term and is significant superior to angiography guided PCI. Limitation post hoc analysis, small numbers of patients, and differences in sample size among groups. The study highlighted the role of IC imaging during

La Facultad de Ciencias Medicas de la Universidad de Buenos Aires publico un libro con las resenas de los medicos argentinos con mas contribuciones en su especialidad Muy honrado de haber sido incluido en esa lista.

Happy Day to all interventionalist worldwide Today, we missed Dr's Carlos Fernandez-Pereira and Jorge Restagno

Complete FFF guided vs. culprit artery only in patients with Non-STEMI Complete significantly lower the composite end point, mainly driving by repeat revascularization. However, all cause and cardiac death were similar. We have to take into account that Syntax Score was low. In

PULSE: CCTA results after unprotected LMCA stenting with DES didn't reduce primary endpoint. I am not surprised with these negative results.When interventionalist understand that ISR and stent thrombosis are not a limitation of current DES design, we will be able to reduce

This year, we will be honored with these guest faculty members of our symposium together with SAC and Sanatorio Otamendi.

Patients with cardiac arrest out of hospital without STEMI angiography immediately didn't improve one year outcome. Limitations of this metaanalysis: Only two trials were analyzed. Too small for a metaanalysis. https://t.co/buX4VlyL5g

Nice rrvision. i highly recommend it. I remember my 1st SCAD in an immediately postpartum young girl with a critical spiral of multiple lesions into LAD. We stenting all the way down with GR II stents. The patient never had recurrence, and I still saw her. Last year, I

Nice review of PFO closure benefit, taking into account clinical and anatomic features (PASCAL). In those with these high-risk clinical and anatomic conditions, the benefit of PFO closure is clear. I am tired of arguing with internalist and neurologist about this topic.

Amazing article in NEJM Over 2 million people in 6 continents 39 countries. In all of them, the reduction of risk factors such hypertension obesity diabetes dyslipemia and SMOKING prolong life in men and women. https://t.co/lCzlX9n0el

Maybe this important data should be read for all people who are in charge of the indication and final approval of this technique in clinical practice in Argentina. 15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism: Insights From the PROLONG Registry | JACC:

I am fascinated with this topic Statins didn't reduce Lp(a) levels. Is that meaning beneficial effects of statin is in those patient at low risk in developing CAD disease ? Effect of Lipid-lowering Therapies on Lipoprotein(a) Levels: A Comprehensive Meta-analysis of Randomized

Cerebral Protection Devices have a rationality to use in some complex heavy calcified aortic stenosis during TAVI procedures.However, disabling stroke after TAVI, it is strongly related to implantation strategy. In my personal practice, in the last 15 years, I didn't remember

Early invasive vs. conservative strategy in elderly patients with ACS. A metaanalysis found no differences in all cause of death but lower incidence of MI and TVR in the invasive arm. Conservative strategy found less bleeding. More data is needed.I wonder if all cause of death

Institutional variability in the US with STEMI. Large registry with amazing similarities that were observed by the registry of Giuseppe De Luca and also in our LATAM registry . Now in JAMA Cardiology. https://t.co/1UKw4oXDZO

ACC/AHA Statement of ACS guideliness. Latin America Perspective. Useful Commentary in JACC. https://t.co/xr8YJ8LBxl

Causes of death in the USA from 2019 to 2023 in the national registry. Cardiac death despite new technologies and new drugs increased compared 2019 to 2023 https://t.co/vAaTT1zlY6

Colchicine in secondary prevention for CAD 12% MACE reduction Trials summary at EHJ https://t.co/H2vMi7j5Rk